Works Cited

1. Gervasini G, Benítez J, Carrillo J. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755-774.

2. Wu AH. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. Arch Pathol Lab Med. 2013;137(9):1232-1236.

3. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at Last accessed April 23, 2021.

4. Kim S, Yun YM, Chae HJ, et al. Clinical pharmacogenetic testing and application: laboratory medicine clinical practice guidelines. Ann Lab Med. 2017;37(2):180-193.

5. Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol. 2012;74(4):698-721.

6. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388-394.

7. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.

8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphism and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.

9. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.

10. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7(8):1211-1221.

11. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte: an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.

12. Pop TR, Chirită DN, Buzoianu AD. Pharmacogenetics of oral anticoagulant therapy. Hum Vet Med. 2013;5(1):9-13.

13. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin Pharmacol Ther. 2009;86(1):109-113.

14. Alonso SG, de la Torre Díez I, Zapiraín BG. Predictive, personalized, preventive and participatory (4P) medicine applied to telemedicine and eHealth in the literature. J Med Syst. 2019;43(5):140.

15. Cardon LR, Harris T. Precision medicine, genomics and drug discovery. Hum Mol Genet. 2016;25(R2):R166-R172.

16. Hood E. Pharmacogenetics: the promise of personalized medicine. Environ Health Perspect. 2003;111(11):A581-A589.

17. Haga SP, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med. 2008;10(6):391-395.

18. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.

19. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13): 3908-3914.

20. Cavallari L, Shin J, Perera, MA. Role of pharmacogenetics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011;31(12):1192-1207.

21. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood. 2010;115(18):3827-3834.

22. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13(12):3731-3737.

23. Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2011;11(3):214-226.

24. Dreussi E, Cecchin E, Polesel J, et al. Pharmacogenetics biomarkers and their specific role in neoadjuvant chemoradiotherapy treatments: an exploratory study on rectal cancer patients. Int J Mol Sci. 2016;17(9):1482.

25. Carrieri D, Bewshea C, Walker G, et al. Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting report. J Med Ethics. 2016;42(11):695-697.

26. Vogenberg FR, Barash CI, Pursel M. Personalized medicine, part 2: ethical, legal and regulatory issues. P T. 2010;35(11):624-626, 628-631, 642.

27. Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in three "early adopting" departments of psychiatry. J Clin Psychiatry. 2010;71(6):745-753.

28. Barash CI. Ethical Issues in Pharmacogenetics. Available at Last accessed April 23, 2021.

29. American Academy of Pediatrics. Ethical and policy in genetic testing and screening of children. Pediatrics. 2013;131(3):620-622.

30. Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff (Millwood). 2018;37(5):717-723.

31. Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2014;96(6):652-654.

32. Lazaridis KN. Improving therapeutic odyssey: preemptive pharmacogenomics utility in patient care. Clin Pharmacol Ther. 2017;101(1):39-41.

33. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25-33.

34. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89-106.

35. Feldman EA. The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med. 2012;27(6):743-746.

36. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209-217.

37. Luzum JA, Pakyz RE, Elsey AR, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther. 2017;102(3):502-510.

Evidence-Based Practice Recommendations Citations

1. Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15(5):399-407. Available at Last accessed April 28, 2021.

Copyright © 2021 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.